SEPTInvestingStart Free

PCRX 10-Q: Material agreement

Filed with the SEC on · accession 0001628280-26-071136

PCRX filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved +0.1% by the first close after the filing.

Summary of the filing

Pacira Pharmaceuticals amended its Manufacturing and Supply Agreement with Patheon UK Limited to extend the contract term from October 2027 to December 31, 2031, and to revise pricing, volume commitments, and forecast obligations for the ZILRETTA drug product.

For details, click here →How to read a 10-Q →

Key details

Contracting party; subsidiary of pacira biosciences, inc.Pacira Pharmaceuticals, Inc.
Contracting party; manufacturing services providerPatheon UK Limited
Original contracting party; acquired by pacira biosciences, inc.Flexion Therapeutics, Inc.
General manager, patheon uk limitedColin Drummond
Associate general counsel, pacira pharmaceuticals, inc.Elena McDermott

How PCRX stock reacted

Close before

$36.40

Nov 4, 2026

First close after

+0.05%

$36.42

5 trading days

—

Since filing

+0.11%

$36.44

✦ Ask GOAX AI about this filing — what it means for PCRX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for PCRX?

Click here

Frequently asked questions

What did PCRX file with the SEC on Nov 5, 2026?

PCRX filed a 10-Q (Material agreement). Pacira Pharmaceuticals amended its Manufacturing and Supply Agreement with Patheon UK Limited to extend the contract term from October 2027 to December 31, 2031, and to revise pricing, volume commitments, and forecast obligations for the ZILRETTA drug product.

What does a material agreement mean for PCRX stock?

A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

How did PCRX stock react to this filing?

PCRX closed at $36.40 before the filing and $36.42 on Nov 5, 2026 (+0.05%).

Other PCRX SEC filings

Get alerts when PCRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
PCRX overviewPCRX analysisPCRX newsLatest SEC filings